menu
    • menu

    Company profile for Rhythm Pharmaceuticals

    NEW Drugs in Dev: 6
    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-03-23

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Rhythm is a late-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of rare genetic disorders of obesity. The company recently announced positive topline results from pivotal Phase 3 clinical trials of setmelanotide, its MC4R agonist, in people living with POMC deficiency obesity and LEPR deficiency obesity and plans to complete its first rolling NDA submission to th...
    Rhythm is a late-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of rare genetic disorders of obesity. The company recently announced positive topline results from pivotal Phase 3 clinical trials of setmelanotide, its MC4R agonist, in people living with POMC deficiency obesity and LEPR deficiency obesity and plans to complete its first rolling NDA submission to the FDA in the first quarter of 2020.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Rhythm PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Rhythm Pharmaceuticals, Inc. 222 Berkeley Street, 12th Floor Boston, MA 02116
    Telephone
    Telephone
    857-264-4280
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.rhythmtx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/rhythm-pharmaceuticals-inc-
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/rhythmpharma

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    IPhEB Russia

    Not Confirmed

    envelop Contact Supplier

    IPhEB Russia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Rhythm Pharma Receives Positive CHMP Opinion for IMCIVREE
    Rhythm Pharma Receives Positive CHMP Opinion for IMCIVREE

    26 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/26/3263104/0/en/Rhythm-Pharmaceuticals-Receives-Positive-CHMP-Opinion-for-IMCIVREE-setmelanotide-for-the-Treatment-of-Obesity-and-Control-of-Hunger-in-Patients-with-Acquired-Hypothalamic-Obesity-d.html

    GLOBENEWSWIRE
    26 Mar 2026
    Share Share
    Rhythm Pharma Names PANTHERx Rare Exclusive U.S. Specialty
    Rhythm Pharma Names PANTHERx Rare Exclusive U.S. Specialty

    20 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/pantherx-rare-selected-by-rhythm-pharmaceuticals-inc-as-the-exclusive-us-specialty-pharmacy-for-the-expanded-indication-for-imcivree-setmelanotide-302720005.html

    PR NEWSWIRE
    20 Mar 2026
    Share Share
    FDA Approves IMCIVREE for Acquired Hypothalamic Obesity
    FDA Approves IMCIVREE for Acquired Hypothalamic Obesity

    19 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/19/3259502/0/en/Rhythm-Pharmaceuticals-Announces-FDA-Approval-of-IMCIVREE-setmelanotide-for-Patients-with-Acquired-Hypothalamic-Obesity.html

    GLOBENEWSWIRE
    19 Mar 2026
    Share Share
    Revolution, Ascendis Seen As Top Buyout Targets In Biopharma
    Revolution, Ascendis Seen As Top Buyout Targets In Biopharma

    19 Mar 2026

    // BIOSPACE

    https://www.biospace.com/business/as-analysts-await-pharma-on-pharma-megadeals-biotechs-offer-attractive-alternatives-for-the-cautious

    BIOSPACE
    19 Mar 2026
    Share Share
    Rhythm Pharma Reveals Phase 3 EMANATE Trial Topline Results
    Rhythm Pharma Reveals Phase 3 EMANATE Trial Topline Results

    16 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/16/3256684/0/en/Rhythm-Pharmaceuticals-Announces-Topline-Results-from-Phase-3-EMANATE-Trial.html

    GLOBENEWSWIRE
    16 Mar 2026
    Share Share
    Rhythm Pharma Reveals More Positive Phase 3 Setmelanotide Data
    Rhythm Pharma Reveals More Positive Phase 3 Setmelanotide Data

    01 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/01/3246959/0/en/Rhythm-Pharmaceuticals-Announces-Additional-Positive-Data-from-Phase-3-TRANSCEND-trial-of-Setmelanotide-in-Patients-with-Acquired-Hypothalamic-Obesity.html

    GLOBENEWSWIRE
    01 Mar 2026
    Share Share

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search